Interpace Biosciences, Inc.
IDXG
$1.98
-$0.01-0.50%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 266.68% | -44.65% | -0.20% | 230.64% | 242.99% |
| Total Depreciation and Amortization | 9.76% | 12.17% | -10.95% | -38.45% | -53.28% |
| Total Amortization of Deferred Charges | -- | -- | 85.71% | -60.71% | -- |
| Total Other Non-Cash Items | -2,498.05% | -46.55% | -5.21% | -45.39% | -38.89% |
| Change in Net Operating Assets | 135.04% | 91.59% | 55.88% | -36.91% | -197.65% |
| Cash from Operations | 25.51% | 5.98% | 40.77% | 128.60% | 22.62% |
| Capital Expenditure | 59.36% | 49.72% | -64.16% | -95.84% | -86.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 59.36% | 49.72% | -4,384.21% | -1,596.00% | -906.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 21.43% | -19.51% | -34.15% | -132.14% | -124.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 60.87% | -43.75% | -43.75% | -43.75% | -43.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 91.93% | 93.04% | 93.04% | 93.56% | 93.56% |
| Cash from Financing | 23.70% | 22.80% | 13.75% | -25.79% | -15.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 151.25% | 76.36% | 50.42% | 41.95% | -53.16% |